type 2 diabetes mellitus. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: The intervention group every two weeks receives a soft Vitamin D Placebo Capsule (Oral Paraffin, Tabriz Zahrawi Company) for 16 weeks. Intervention 2: The control group consumes a plac
Treatment - Other
The intervention group every two weeks receives a soft Vitamin D Placebo Capsule (Oral Paraffin, Tabriz Zahrawi Company) for 16 weeks.
The control group consumes a placebo capsule of vitamin D (oral paraffin, Zahravi, Tabriz) every two weeks for 16 weeks .
Sponsors
Vice chancellor for research,Isfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
35 Years to 60 Years
Inclusion criteria
Inclusion criteria: Tendency to cooperate with research project Fasting blood higher than 126 milligram per deciliter or a two-hour blood sugar higher than 200 milligram per deciliter Age: 20 to 50 years; serum 25 Hydroxy vitamin D level less than 30 nanogram per milliliter Detection of mild or severe anxiety by the DASS21 questionnaire
Exclusion criteria
Exclusion criteria: Have not past medical history of attack or stroke; Severe depression in the previous years Taking Orlistat drugs (Venostat, Zenical) and anti-epileptic drugs such as phenobarbital and phenytoin Taking any supplements such as multivitamin and vitamin d during the 4 months prior to the study Smoking , alcohol intake pregnancy or lactation Not wanting to continued cooperation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaspin hormone serum levels. Timepoint: Before and 16 weeks after the start of intervention. Method of measurement: Blood testing (by ELISA kit).;Omentin hormone serum levels. Timepoint: Before and 16 weeks after the start of intervention. Method of measurement: Blood testing (by ELISA kit).;Interleukin-10 serum levels. Timepoint: Before and 16 weeks after the start of intervention. Method of measurement: Blood testing (by ELISA kit).;CRP serum levels. Timepoint: Before and 16 weeks after the start of intervention. Method of measurement: Blood testing (by ELISA kit).;Anxiety score. Timepoint: Before and 16 weeks after the start of intervention. Method of measurement: by DASS21 questionnaire.;Depression score. Timepoint: Before and 16 weeks after the start of intervention. Method of measurement: by DASS21 questionnaire.;Stress score. Timepoint: Before and 16 weeks after the start of intervention. Method of measurement: by DASS21 questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| BMI. Timepoint: Before and 16 weeks after the start of intervention. Method of measurement: computing.;Waist circumference. Timepoint: Before and 16 weeks after the start of intervention. Method of measurement: Strip meter.;Weight. Timepoint: Before and 16 weeks after the start of intervention. Method of measurement: Scales.;Vitamin D serum levels. Timepoint: Before and 16 weeks after the start of intervention. Method of measurement: Blood testing (by ELISA kit). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSiavash Fazelian
Isfahan University of Medical Sciences
Outcome results
None listed